Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
Alessandra Fabi(Agostino Gemelli University Polyclinic), F. Cognetti(Sapienza University of Rome), Marcella Mottolese, Alessandra Felici, Nello Salesi(Tumori Foundation), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), Armando Carpino(Cancer Institute (WIA)), Isabella Sperduti(San Gallicano Hospital), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Vito Lorusso, Anna Maria Cianciulli, Mariangela Ciccarese, Paolo Carlini(National Cancer Institute)
Cited by 20
Related Papers
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
|Annals of Oncology|2016|398
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab
|Clinical Cancer Research|2019|240